Bruker has appointed physician-scientist, biotechnology entrepreneur, and immunology researcher Eicke Latz to its board of directors, effective January 1, 2027.
Latz is internationally recognized for his work in innate immunity and inflammation. His research and entrepreneurial activities have helped advance therapeutic programs from early scientific discovery into clinical development.
He currently serves as scientific director of the German Rheumatology Research Center and professor of experimental rheumatology at Charité Universitätsmedizin Berlin.
Latz previously founded and led the Institute of Innate Immunity at the University of Bonn. His experience also includes government advisory work, biotechnology formation and scaling, and senior advisory positions with major pharmaceutical companies.
Building Biotechnology Companies From Immunology Research
Latz has co-founded five biotechnology companies: IFM Therapeutics, Odyssey Therapeutics, Metaimmune Therapeutics, DiosCure Therapeutics, and Beren Therapeutics.
These businesses have focused on translating discoveries in inflammation and innate immunity into potential medicines. Their programs have progressed into clinical development and contributed to successful acquisitions and public offerings.
Bruker expects Latz’s scientific, medical, entrepreneurial, and organizational experience to support its strategy in post-genomic life-science tools.
The company develops research instruments and analytical and diagnostic products used in proteomics, multiomics, spatial biology, single-cell biology, molecular diagnostics, clinical microbiology, microscopy, preclinical imaging, and semiconductor metrology.
His appointment adds a disease-biology and drug-development perspective as Bruker expands its technologies for biomarker research and biopharmaceutical discovery.
KEY QUOTES:
Eicke brings a rare combination of world-class disease biology leadership, remarkable biopharma entrepreneurial success, and medical institute strategic leadership to our board. As Bruker expands its leadership in post-genomic life-science tools for disease biology research, molecular diagnostics, and biopharma drug discovery and development, Eicke’s scientific-medical vision, biopharma insights, strategic and leadership experience will be very valuable to Bruker.
Frank H. Laukien, Chairman, President and CEO of Bruker
It’s a great honor to join the Board of Directors at Bruker Corporation, a company at the forefront of AI-accelerated, deep functional proteomics, multiomics and spatial biology research. I see Bruker as uniquely positioned to enable significant advancements in disease biology research, novel biomarker discovery, and next-generation proteomic molecular diagnostics, and I am very excited to contribute.
Eicke Latz, Incoming Director at Bruker

